NeuroRx's NRX-101 improves depression and suicidality in Phase II

NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial to treat severe bipolar depression and acute suicidal ideation and behavior. Data were presented in

Read the full 311 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE